A Science Magazine feature article focuses on the development of an artificial red blood cell substitute, ErythroMer, that is being developed by KaloCyte, a UM Ventures, Baltimore portfolio company. KaloCyte is partnering with the University of Maryland School of Medicine (UMSOM) on a $46 million Defense Advanced Research Projects Agency (DARPA) grant to develop a shelfstable, field-deployable whole blood substitute with ErythroMer as its core. Allan Doctor, MD, UMSOM professor and director of the school's Center for Blood Oxygen Transport and Hemostasis and KaloCyte's co-founder and  chief science officer, is leading the research consortium.

Read the full article from Science.